KRAS and colorectal carcinoma: The availability of highly specific, clinical grade drugs will allow running dedicated clinical trials on CRC patients bearing KRAS- and BRAF-mutant tumors that compare the efficacy and safety of metabolism-targeting agents with that of angiogenesis inhibitors.